How Risky Is Amgen's At-Risk Launch Of Herceptin, Avastin Biosimilars?

In ongoing patent litigation with Genentech, Amgen may need to reveal its counsel's advice on whether it should launch, while Genentech must produce its settlement agreements with Mylan, Celltrion, and Pfizer.